Today: 10 November 2025
Subscribe
Browse Category

NYSE:KVUE News 14 October 2025 - 9 November 2025

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

NJ Stock: What to Know Before the Bell on November 10, 2025 (Fresh FDA Wins, Dividend Date, and Legal Overhang)

Dateline: Monday, November 10, 2025 — pre‑market Johnson & Johnson (NYSE: JNJ) starts the new week with momentum from multiple drug approvals, a firm dividend timetable, and a still‑active litigation backdrop. Here’s a concise, investor‑focused briefing on the key developments likely to guide JNJ sentiment before the U.S. market opens today. Key takeaways• Q3 beat and higher 2025 sales outlook; adjusted EPS guidance reaffirmed. JNJ.com+1• Two fresh FDA wins in the past few weeks: Caplyta add‑on use in depression and Darzalex Faspro for high‑risk smoldering myeloma. Reuters+1• Inlexzo bladder‑cancer device approval broadens 2025 product catalysts. U.S. Food and Drug Administration•
9 November 2025
 ·  ·  ·  ·  ·  ·  · 
P&G Earnings Smash Estimates – Beauty Boom and Razors Fly Off Shelves in Q1

PG Stock Today: What to Know Before the Bell on November 10, 2025 (Earnings, Dividend, Tariffs, and Sector M&A)

Summary (read this first)• PG closed Friday, November 7 at $146.98, sitting near the low end of its 52‑week range ($144.46–$180.43). Market cap is about $343B. StockAnalysis+1• P&G’s latest quarter (reported Oct. 24) delivered net sales of $22.4B (+3% y/y), organic sales +2%, and core EPS of $1.99 (+3%). FY26 guidance: all‑in sales +1% to +5%, core EPS $6.83–$7.09; management now bakes in ~$400M after‑tax tariff headwind and ~$100M commodity headwind, offset by an FX tailwind of ~$300M. PG Investor• Dividend watch: the next $1.0568 per‑share payout lands Monday, November 17 (ex‑date was Oct. 24). Trailing forward yield is ~2.9%
9 November 2025
 ·  ·  ·  ·  ·  ·  · 
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Company Overview & History Kenvue Inc. is a leading consumer health company formed from Johnson & Johnson’s storied consumer products division. The name “Kenvue” combines “ken” (knowledge) and “vue” (view), reflecting a vision of insight-driven care en.wikipedia.org. As a spin-off, Kenvue took over J&J’s well-known retail brands, ranging from over-the-counter (OTC) medicines to skincare and baby care. Today its portfolio spans three segments investing.com: Formally incorporated in 2022, Kenvue began trading on the NYSE (ticker KVUE) in May 2023 after a highly anticipated IPO en.wikipedia.org. The IPO raised $3.8 billion – the largest U.S. listing in nearly two years – and
4 November 2025
 ·  ·  ·  ·  ·  ·  · 
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Stock Price and Intraday Performance (Nov 3, 2025) Kenvue’s stock soared on the buyout news, delivering a sharp one-day gain. As of midday Nov. 3, KVUE traded around $17–$18, up roughly 18–20% intraday reuters.com. Prior to the announcement, the stock had closed at $14.37 on Oct. 31 stockanalysis.com, near its 52-week low of ~$14.02 reuters.com reuters.com. The takeover premium (deal valued at ~$21.01 per share) immediately boosted KVUE, though the share price remained a bit below the offer value – typical in cash/stock mergers as arbitragers factor in execution timing and Kimberly-Clark’s own stock movement (KMB shares fell ~12.5% on
3 November 2025
 ·  ·  ·  ·  ·  · 
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Stock Hits a 52-Week Low on Legal Woes Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge stocktwits.com. The one-day drop – Kenvue’s worst on record – was triggered by headline risks that blindsided investors. By early Friday, October 17, the stock stabilized slightly (up about 0.6% in pre-market trading) after the rout stocktwits.com. Still, at roughly 40% below its IPO price, the Johnson & Johnson spinoff has seen its market capitalization shrink to about $30–31 billion reuters.com. This dramatic sell-off came despite broader markets being relatively calm – the S&P
17 October 2025
 ·  ·  ·  ·  · 
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

Recent Market Moves Kenvue’s stock (NYSE: KVUE) has been volatile. On Oct 16, 2025 it closed around $15.46, marking a fresh 52-week low investing.com. Over the prior week the shares had slid ~13%, partly driven by jitters over UK talc lawsuits and Trump-era Tylenol claims. Investors bid on options, with call volume surging 52% on Oct 13 marketbeat.com, even as the stock dipped 2.9% that day to $16.17 marketbeat.com. Year-to-date KVUE is roughly flat to down modestly, but it lags the broader market. For context, the S&P 500 was nearly unchanged while Kenvue was down ~5% on Oct 16. A
16 October 2025
 ·  ·  ·  ·  · 
J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

J&J Makes Bold Move: Orthopedics Spin-Off (“DePuy Synthes”) Announced – 2025 Forecast Raised

Background: J&J’s Three-Way Split Strategy Johnson & Johnson, a healthcare conglomerate, historically consisted of consumer health, pharmaceutical (Innovative Medicine), and medical technology divisions. In 2023 J&J spun off its consumer products (Tylenol, Band-Aid, Neutrogena, etc.) into a new public company, Kenvue (KVUE). Now it is moving a second business out: the orthopedics arm of its MedTech division. The spin-off means J&J will remain focused on pharmaceuticals and higher-growth medical devices, while DePuy Synthes (named after J&J’s long-time orthopedics brand) inherits the hip/knee/shoulder implant and surgical tools business reuters.com jnj.com. Spin-offs are commonly used to allow each entity to pursue tailored
14 October 2025
 ·  ·  ·  ·  ·  · 
Go toTop